Management and Treatment of IgM Deficiency

Diagnostic Evaluation Before Treatment

The American Academy of Allergy, Asthma, and Immunology recommends confirming the diagnosis with repeated measurements of serum IgM levels below the age-specific normal range 1
Evaluate specific antibody production by measuring responses to pneumococcal vaccines, as recommended by the American Academy of Allergy, Asthma, and Immunology 3, 4
Assess lymphocyte subsets by flow cytometry, particularly memory B-cell counts, according to the American Academy of Allergy, Asthma, and Immunology 1

The American Academy of Allergy, Asthma, and Immunology suggests prophylactic antibiotics for patients with recurrent respiratory infections, with options including amoxicillin, trimethoprim/sulfamethoxazole, or macrolides 5
Immunoglobulin replacement therapy is indicated for patients with evidence of bronchiectasis or other permanent organ damage, as recommended by the American Academy of Allergy, Asthma, and Immunology 6

The typical starting dose of intravenous immunoglobulin (IVIG) is 400-600 mg/kg, with adjustments based on clinical response and trough IgG levels, according to the American Academy of Allergy, Asthma, and Immunology 6, 7

Regular monitoring of IgG trough levels every 6-12 months is recommended by the American Academy of Allergy, Asthma, and Immunology 7
Monitor complete blood counts and serum chemistry, and assess clinical response by tracking frequency and severity of infections, as suggested by the American Academy of Allergy, Asthma, and Immunology 7
For patients with low IgM and IgA, monitor these levels during treatment as increases may indicate improvement, according to the American Academy of Allergy, Asthma, and Immunology 1, 3

Transient IgM deficiency may resolve spontaneously, particularly in children, and consideration should be given to reassessing immune function after 3-6 months of therapy, as recommended by the American Academy of Allergy, Asthma, and Immunology 1, 3
IgA deficiency is not a contraindication to IgG therapy, though very rare anaphylactic reactions have been reported, according to the American Academy of Allergy, Asthma, and Immunology 7

Early treatment helps prevent permanent organ damage such as bronchiectasis, as recommended by the American Academy of Allergy, Asthma, and Immunology 6

Central venous access solely for IVIG administration should be avoided due to infection risk, as suggested by the American Academy of Allergy, Asthma, and Immunology 5